JPRN-UMIN000012522已完成3 期
Efficacy and Safety of Cytokines Versus Sunitinib as First-line Followed by Second-line Axitinib in the Treatment of Patients with Metastatic Renal Cell Carcinoma: A Phase III Randomized Sequential Open-Label Study - ESCAPE Study
Innovative Clinical Research Center, Kanazawa University Hospital0 个研究点目标入组 144 人开始时间: 2013年12月9日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 144
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 80years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1. Patients with history of hypersensitivity against IFN, IL-2, Sunitinib, or Axitinib 2. Pregnant, pregnancy suspect, nursing women, patients who plan to have a baby (including men) 3. Patients with a history of hypersensitivity to biological preparations such as vaccines 4. Patients having Shou-Sai-Kotou (special herbal drug) 5. Patients with autoimmune hepatitis 6. Patients with a history of interstitial pneumonia 7. Patients treated for another primary malignancy within 3 years of enrollment 8. Patients judged ineligible to participate in the study by the investigator
研究者
相似试验
Unknown
3 期
Comparison of Sequential Therapies With Sunitinib and Sorafenib in Advanced Renal Cell CarcinomaMetastatic Renal Cell CarcinomaNCT01481870Yamagata University120
招募中
不适用
Safety and Efficacy of Sunitinib Given in Schedule Modification in Patients with Advanced Renal Cell Carcinoma (RCC)Renal Cell CarcinomaJPRN-UMIN000011649Osaka University Graduate School of Medicine132
尚未招募
2 期
Improving sunitinib efficacy and tolerability in patients with metastatic clear cell carcinoma of the kidney by using a 14/7 day schedule and toxicity-adjusted dosingMetastatic Renal Cell CancerCancer - KidneyACTRN12616001639415Macquarie University80
撤回
4 期
Study on the influence of sunitinib and sorafenib on cognitive functioning a cross sectional study (UMCNONCO200901)gastro intestinal stromacel tumorkidney cancer10038364GISTNL-OMON32837niversitair Medisch Centrum Sint Radboud80
已完成
不适用
Study of the Immunoresponse in Patients Treated With a Tyrosine Kinase InhibitorGISTRenal Cell CarcinomaNCT00979381Radboud University Medical Center75